Guy MacDonald
Chairman at SCYNEXIS, INC.
Net worth: 47 040 $ as of 2024-03-30
Profile
Guy MacDonald is currently the Chairman at SCYNEXIS, Inc. He previously served as Chairman at F-Star Therapeutics, Inc. and as Director at Tetraphase Pharmaceuticals, Inc. He also held the position of Vice President-Anti Infective & Hospital Products at Merck & Co., Inc. and Executive Vice President-Operations at Idenix Pharmaceuticals LLC.
Mr. MacDonald completed his undergraduate degree at the University Of Dundee.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
SCYNEXIS, INC.
0.09% | 2023-06-14 | 32,000 ( 0.09% ) | 47 040 $ | 2024-03-30 |
Guy MacDonald active positions
Companies | Position | Start |
---|---|---|
SCYNEXIS, INC. | Chairman | 2015-06-03 |
Former positions of Guy MacDonald
Companies | Position | End |
---|---|---|
TETRAPHASE PHARMACEUTICALS, INC. | Chief Executive Officer | 2019-07-31 |
SPRING BANK PHARMACEUTICALS, INC. | Chairman | 2015-08-16 |
IDENIX PHARMACEUTICALS INC | Chief Operating Officer | 2007-12-31 |
MERCK & CO., INC. | Corporate Officer/Principal | 2002-12-31 |
Training of Guy MacDonald
University Of Dundee | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
MERCK & CO., INC. | Health Technology |
SCYNEXIS, INC. | Health Technology |
Private companies | 3 |
---|---|
Idenix Pharmaceuticals LLC
Idenix Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Idenix Pharmaceuticals LLC is a biopharmaceutical company, which is engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. Currently, its primary research and development focus is on the treatment of patients with hepatitis C virus, or HCV, using nucleotide polymerase inhibitors and NS5A inhibitors. Idenix Pharmaceuticals was founded by Jean-Pierre Sommadossi and Raymond F. Schinazi in May 1998 and is headquartered in Cambridge, MA. | Health Technology |
Tetraphase Pharmaceuticals, Inc.
Tetraphase Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetraphase Pharmaceuticals, Inc. is engaged in the development and production of novel tetracyclines for serious and life-threatening bacterial infections. It also develops eravacycline, a synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Waltham, MA. | Health Technology |
F-Star Therapeutics, Inc. (United States)
F-Star Therapeutics, Inc. (United States) Pharmaceuticals: MajorHealth Technology F-Star Therapeutics, Inc. engages in discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. Its products are used for the treatment of viral infections, inflammatory diseases, and certain cancers. The company was founded by Douglas J. Jensen and Radhakrishnan P. Iyer on October 7, 2002 and is headquartered in Hopkinton, MA. | Health Technology |
- Stock Market
- Insiders
- Guy MacDonald